Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD
- Registration Number
- NCT00098228
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 686
- Diagnosis of COPD
- Age 40-75 years
- Smoking history
- Other serious disease
- Allergy to QAB149
- Respiratory tract infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pulmonary function measured between 22 and 24 hours after dosing on Day 1
- Secondary Outcome Measures
Name Time Method Safety measurements Pulmonary function measured on days 1 and 7 at various intervals after dosing
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (54)
UAB Pulmonary Research
🇺🇸Birmingham, Alabama, United States
Diagnostic & Medical Clinic
🇺🇸Mobile, Alabama, United States
The University of South Alabama Medical Center
🇺🇸Mobile, Alabama, United States
Pulmonary Associates
🇺🇸Phoenix, Arizona, United States
USC Rancho Amigos Medical Center
🇺🇸Downey, California, United States
Radiant Research
🇺🇸Encinitas, California, United States
Allergy Research Foundation , Inc
🇺🇸Los Angeles, California, United States
David Geffin UCLA School of Medicine
🇺🇸Los Angeles, California, United States
Southern California Research
🇺🇸Mission Viejo, California, United States
California Allergy & Asthma Medical Group
🇺🇸Palmdale, California, United States
Scroll for more (44 remaining)UAB Pulmonary Research🇺🇸Birmingham, Alabama, United States